Cannabis and Biotech Stocks Ready to Surge

HENDERSON, NV / ACCESSWIRE / February 11, 2019 / One stock you should research right away is, BioRestorative Therapies, Inc. (BRTX) a life sciences company focused on stem cell-based therapies, is developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue. The company traded above $3 dollars last year before hitting lows with the rest of the biotech industry. The company has started to rally in lockstep with the industry's ETF: IBB, and could be on the verge of a breakout that may send BRTX above their 2018 highs. Get a jumpstart on the crowd by researching BRTX today.

Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Scotts Miracle-Gro Company (SMG), Aurora Cannabis, Inc. (ACB), The Green Organic Dutchman (TGODF), and OrganiGram Holdings, Inc. (OGRMF).

According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.

One of the more novel approaches to fighting this obesity epidemic is being developed by, BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.318M Share Price: $0.729) a life sciences company focused on stem cell-based therapies, developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span the US, Australia, and Japan.

Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.

___

Scotts Miracle-Gro Company (SMG) (Market Cap: $4.10B Share Price: $74.18). The company released financial results for the first quarter of fiscal 2019, including revenue growth of 35 percent on the year, driven by a substantial uptick registered by the Hawthorne subsidiary that caters to cannabis growers.

___

One cannabis producer in line to benefit from industry growth in most variances like CLSK and SMG is

Aurora Cannabis Inc. (ACB) (Market Cap: $7.38B Share Price: $7.40). The company has a production capacity of roughly 150,000 kilograms of cannabis per year. That number is expected to more than triple to 500,000 by mid-2020. Investors have been buoyed by the company's recent report of revenue rising to $29.9 million in the second quarter to Dec. 29, up 40% from the prior quarter. Proforma revenue, which includes revenue from pending acquisitions came to $49.5 million.

___

The Green Organic Dutchman (TGODF) (Market Cap: $758.92M Share Price: $2.82) is a Canadian Licensed Producer growing out of Quebec. According to their investor information, they currently are growing on 620,000 square feet and are expanding to reach 970,000 square feet. Their website also states that they can produce 116,000 kg of cannabis per year. The company just announced that the Danish Medicines Agency, the Government body responsible for issuing cannabis related licenses, has granted an initial cannabis business authorization to TGODF's joint venture production partner Knud Jepsen. This licence will allow TGOD's JV partner Kund Jepsen to immediately begin importation of starting materials and to begin research and development related to the creation of elite cannabis genetics.

----

OrganiGram Holdings, Inc. (OGRMF) (Market Cap: $777.77M Share Price: $6.00) a cannabis producer just announced they are adding grow rooms which will more than triple target annual production capacity to 113,000 kg once complete.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting''). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is apart of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority and does not provide or claim to provide investment advice.